PASG Logo

Passage Bio, Inc. (PASG) 

NASDAQ
Market Cap
$32.13M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
657 of 774
Rank in Industry
356 of 432

Largest Insider Buys in Sector

PASG Stock Price History Chart

PASG Stock Performance

About Passage Bio, Inc.

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the …

Insider Activity of Passage Bio, Inc.

Over the last 12 months, insiders at Passage Bio, Inc. have bought $0 and sold $216,136 worth of Passage Bio, Inc. stock.

On average, over the past 5 years, insiders at Passage Bio, Inc. have bought $23.52M and sold $246,548 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 575,195 shares for transaction amount of $483,164 was made by ORBIMED ADVISORS LLC (10 percent owner) on 2023‑06‑28.

List of Insider Buy and Sell Transactions, Passage Bio, Inc.

2024-09-19Sale10 percent owner
39,300
0.0645%
$0.71$27,903-12.49%
2024-09-18Sale10 percent owner
25,631
0.0432%
$0.73$18,711-12.55%
2024-09-17Sale10 percent owner
111,400
0.181%
$0.73$81,322-15.57%
2024-09-16Sale10 percent owner
63,100
0.1035%
$0.74$46,694-15.81%
2024-02-13SaleCHIEF MEDICAL OFFICER
1,638
0.0029%
$0.97$1,589+9.09%
2024-02-13SaleSVP, INTERIM CFO
1,470
0.0026%
$0.97$1,426+9.09%
2024-01-02SaleGC & Corporate Secretary
15,813
0.0291%
$0.91$14,390+10.63%
2024-01-02SaleChief Medical Officer
15,813
0.0291%
$0.91$14,390+10.63%
2024-01-02SaleSVP, Interim CFO
10,672
0.0197%
$0.91$9,712+10.63%
2023-07-28SaleChief Financial Officer
11,453
0.021%
$0.88$10,079+5.64%
2023-06-28Purchase10 percent owner
575,195
1.0841%
$0.84$483,164+14.66%
2023-06-27Purchase10 percent owner
617,382
1.144%
$0.84$518,601+12.39%
2023-06-16SaleChief Technical Officer
4,052
0.0072%
$0.93$3,778-3.38%
2023-04-18SaleChief Financial Officer
2,053
0.0037%
$1.05$2,156-13.13%
2022-12-01Saledirector
5,000
0.0092%
$1.19$5,965-17.48%
2022-11-22SaleChief Technical Officer
3,720
0.0076%
$1.33$4,948-17.38%
2022-09-19SaleChief Commercial Officer
1,681
0.0029%
$1.51$2,539-32.92%
2022-05-03Purchase
221,500
0.401%
$1.93$427,495-27.04%
2022-03-21PurchaseCEO and President
10,000
0.0188%
$3.15$31,500-45.31%
2022-01-20Purchase10 percent owner
50,800
0.0975%
$5.00$254,000-58.13%

Insider Historical Profitability

<0.0001%
ORBIMED ADVISORS LLC10 percent owner
7794569
12.6192%
$0.52104<0.0001%
Cale Edgar B.GC & Corporate Secretary
45995
0.0745%
$0.5211<0.0001%
OrbiMed Capital GP VII LLC
6537923
10.5848%
$0.5210<0.0001%
Heron Patrick J
5009219
8.1098%
$0.5210<0.0001%
Frazier Life Sciences IX, L.P.10 percent owner
5009219
8.1098%
$0.5210<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
OrbiMed$13.67M16.4310.12M0%+$00.11
Versant Ventures$6.7M8.054.96M0%+$06.49
Lynx1 Capital Management Lp$6.54M7.864.85M+1,178.06%+$6.03M0.35
New Leaf Venture Partners$3.37M4.052.5M0%+$03.21
The Vanguard Group$2.8M3.362.07M+2.61%+$71,085.59<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.